Geron Stock Discussion

$Geron (GERN.US)$ For those who is new to this company, here is a summary: JNJ paid 250M a year to co develop the drug 5 years ago. They didn’t want to continue the second year which the price was low 5 n drop to lowest of 1.30 in the next 2 years. Gern continue to drug development with the 250M from JNJ to get it FDA approval few months ago to  which they raised 450M for reserve cash. The stock went up to hitting 52 weeks high of 5.34 in the next month or two  of FDA approval. You now are caught...

$Geron (GERN.US)$ this is the month I have been waiting for since Feb as per news on 1) partnership or 2) buy out. Go alone will have its risk n reward which they secure 420M to do it to last early 2026. If its #1 then expect stock 7-8 range, #2- Like to see 10-15 range.Lets beat my #1 niotech buyout imgn return with this prediction.

$Geron (GERN.US)$ Geron Announces Updated Nccn Guidelines® Recommending Rytelo™ (Imetelstat) for the Treatment of Symptomatic Anemia in Patients With Lower-Risk Mds

$Geron (GERN.US)$ Great stock at a great price, time to buy!
折扣价赶快买！

Barclays Initiates Coverage On Geron Corporation with Overweight Rating, Announces Price Target of $9.
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron (GERN.US)$
https://stockregion.app/p/investment-bank-initiates-overweight

🚨 1 AdCom & 3 PDUFA decisions this week:
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline (GSK.US)$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...

$Geron (GERN.US)$
This could get interesting considering the short stats. 
2.85 days to cover.  10.46% short floats.

$Geron (GERN.US)$ Geron (GERN) said Friday it received approval from the US Food and Drug Administration for its drug Rytelo as a treatment of adult patients with lower-risk myelodysplastic syndrome, a type of leukemia.

$Geron (GERN.US)$ 5 dollah